A sizable options order hit the tape today on a stock that has been making headlines recently. A significant options position in UnitedHealth Group (UNH) consisting of 1,426 call option contracts with a $290 strike price expiring December 19, 2025. With the current stock price at $301.65, these calls are already in-the-money by $11.65 per share. The position was executed as a sweep order at $43.53 per contract, representing a total premium investment of approximately $6.2 million.
The V/OI ratio of 1.28 suggests moderately elevated trading activity, with today’s volume exceeding the total open interest by 28%. This LEAPS contract provides the buyer significant time value and represents a substantial bullish position on UNH’s prospects through late 2025. The sweep execution and large contract size indicate institutional-level participation. The in-the-money status suggests a more conservative approach compared to out-of-the-money speculation.
Volume and Open Interest Data
Weekly trading activity for the UNH $290C 12/19/2025 options show a significant spike in volume on June 9, 2025. 10,570 contracts traded hands—an explosive jump from previous days, which only saw 29 contracts on June 6th and 60 on June 5th. Despite this massive surge in trading activity, open interest (OI) barely moved. It increased modestly over earlier days and dropped slightly by 7 contracts on June 9th to settle at 8,188. This divergence between volume and OI strongly suggests that a majority of the contracts traded were likely intraday trades or closing positions, rather than new openings.
The volume/OI ratio of ~1.28 (10,570 / 8,188) reinforces the idea of unusual activity. Standout activity could possibly be either speculative or institutional trades being executed and closed within the same session. Pricing also held relatively stable, closing at $43.90, slightly below the recent high of $44.30. Implied volatility (IV) hovered around 44%, showing minimal fluctuation. Altogether, this pattern points to short-term tactical interest rather than a long-term shift in positioning.
Trade Side Distribution
The trade side distribution for the UNH $290C 12/19/2025 option reveals a notable skew toward bullish sentiment. 59% of the total premium ($6.2M) was executed above the ask. This suggests aggressive buying, likely from market participants eager to secure positions. This is often interpreted as a signal of strong conviction or institutional urgency.
In contrast, 41% of trades ($4.3M) occurred below the bid, which may indicate profit-taking or less confident selling. No trades were executed at the mid, bid, or ask price points, highlighting that this action was decisively outside normal bid/ask behavior. This further emphasizes the unusual nature of the volume. Overall, this distribution supports the view of strong buyer interest behind the recent spike in volume for this LEAPS contract.
What’s Happening with UnitedHealth
UnitedHealth Group (UNH) has recently faced a series of significant challenges impacting its operations and financial standing. In December 2024, Brian Thompson, CEO of UnitedHealthcare, was tragically killed in a targeted attack, leading to heightened security measures for executives and contributing to public scrutiny of the company’s practices. Subsequently, CEO Andrew Witty resigned in May 2025 amid rising medical costs and a Department of Justice investigation into alleged Medicare fraud.
Stephen Hemsley, the former CEO, returned to lead the company, pledging to restore shareholder trust. Financially, UnitedHealth has experienced a substantial decline, with its stock dropping approximately 40% year-to-date, partly due to unexpected losses in its Medicare Advantage segment and the fallout from a 2024 cyberattack on its subsidiary, Change Healthcare. In response to these challenges, the company is refocusing on its U.S. operations, planning to divest its Latin American subsidiary, Banmedica, for around $1 billion.
About UnitedHealth
UnitedHealth Group is a diversified healthcare and insurance company headquartered in the United States, operating primarily through two key segments: UnitedHealthcare and Optum. UnitedHealthcare provides a broad range of health insurance plans and services to individuals, employers, and government programs like Medicare and Medicaid.
Optum, its health services arm, focuses on data-driven care delivery, pharmacy benefits management, and health technology solutions. Together, the company combines clinical expertise, data analytics, and a vast provider network to deliver integrated health solutions aimed at improving outcomes while managing costs across the healthcare ecosystem.
Analyst Ratings
| Firm | Rating | Date Updated |
|---|---|---|
| CFRA | ★★ | 06/08/2025 |
| Market Edge | AVOID | 05/07/2025 |
| Argus | HOLD | 05/15/2025 |
| Morningstar | ★★★★ | 05/22/2025 |
| LSEG | OUTPERFORM | 06/08/2025 |
| Schwab Equity Ratings | B | 06/09/2025 |
Analyst sentiment on UnitedHealth Group (UNH) is mixed to bearish, with a wide range of outlooks reflecting recent company-specific challenges. Two firms—CFRA and Market Edge—issued notably negative stances. CFRA gives UNH a 2-star rating and Market Edge recommends investors to “Avoid” the stock.
Meanwhile, Argus issued a more neutral “Hold” rating, likely reflecting caution amid uncertainty. On the more optimistic end, Morningstar awarded the stock 4 stars. LSEG (London Stock Exchange Group) gave an “Outperform” rating, suggesting confidence in UNH’s longer-term recovery potential. The Schwab Equity Ratings places UNH in category “B”, also implying relative strength versus peers.
This diverse range of ratings highlights a divided analyst community, with some seeing long-term upside while others remain concerned over recent operational and financial turbulence.
Want to see more of these trades? Try out Cheddar Flow free for 7 days. Learn More
Disclaimer: Options trading involves significant risk and is not suitable for all investors. You may lose the entire investment, and certain strategies may result in losses exceeding the initial amount invested. Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice. Always consult a financial or tax advisor before making investment decisions.
